Physical and functional interactions between NSD2 and other chromatin regulators, such as EZH2 and SMARCA2, further reprogram the chromatin landscape, promoting myeloma growth, altering enhancer activity, and sustaining drug resistance [59]. Here, SMARCA2 is linked to plasma cell myeloma.